The etiology and pathogenesis of Alzheimer’s disease (AD) are not fully understood. Thus, there are no drugs available that can provide a cure for it. We and others found that DNA polymerase-β (DNA pol-β) is required for neuronal death in several neurodegenerative models. In the present study, we tested the effect of a DNA pol-β inhibitor 2′,3′– Dideoxycytidine (DDC) in AD models both in vitro and in vivo. DDC protected primary neurons from amyloid-β (Aβ)-induced toxicity by inhibiting aberrant DNA replication mediated by DNA pol– β. Chronic oral administration of DDC alleviated Aβ deposition and memory deficits in the Tg2576 mouse model of AD. Moreover, DDC reversed synaptic loss in Tg2576 mice. These results suggest that DDC represents a novel therapeutic agent for the treatment of AD.
BishopNA, LuT, YanknerBA (2010) Neural mechanisms of ageing and cognitive decline. Nature464, 529–535.
2.
JuckerM, WalkerLC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature501, 45–51.
3.
YangY, MufsonEJ, HerrupK (2003) Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J Neurosci23, 2557–2563.
4.
HoglingerGU, BreunigJJ, DepboyluC, RouauxC, MichelPP, Alvarez-FischerD, BoutillierAL, DegregoriJ, OertelWH, RakicP, HirschEC, HunotS (2007) The pRb/E2F cell-cycle pathway mediates cell death in Parkinson’s disease. Proc Natl Acad Sci U S A104, 3585–3590.
5.
MoschB, MorawskiM, MittagA, LenzD, TarnokA, ArendtT (2007) Aneuploidy and DNA replication in the normal human brain and Alzheimer’s disease. J Neurosci27, 6859–6867.
6.
YangY, GeldmacherDS, HerrupK (2001) DNA replication precedes neuronal cell death in Alzheimer’s disease. J Neurosci21, 2661–2668.
7.
ArendtT (2012) Cell cycle activation and aneuploid neurons in Alzheimer’s disease. Mol Neurobiol46, 125–135.
8.
ZhangZ, CaoX, XiongN, WangH, HuangJ, SunS, LiangZ, WangT (2010) DNA polymerase-beta is required for 1-methyl-4-phenylpyridinium-induced apoptotic death in neurons. Apoptosis15, 105–115.
9.
CopaniA, HoozemansJJ, CaraciF, CalafioreM, Van Haastert ES, VeerhuisR, RozemullerAJ, AronicaE, SortinoMA, NicolettiF (2006) DNA polymerase-beta is expressed early in neurons of Alzheimer’s disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. J Neurosci26, 10949–10957.
10.
CopaniA, SortinoMA, CaricasoleA, ChiechioS, ChisariM, BattagliaG, Giuffrida-StellaAM, VancheriC, NicolettiF (2002) Erratic expression of DNA polymerases by beta-amyloid causes neuronal death. FASEB J16, 2006–2008.
11.
SobolRW, HortonJK, KuhnR, GuH, SinghalRK, PrasadR, RajewskyK, WilsonSH (1996) Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature379, 183–186.
12.
ServantL, BiethA, HayakawaH, CazauxC, HoffmannJS (2002) Involvement of DNA polymerase beta in DNA replication and mutagenic consequences. J Mol Biol315, 1039–1047.
13.
LouatT, ServantL, RolsMP, BiethA, TeissieJ, HoffmannJS, CazauxC (2001) Antitumor activity of 2′,3′-dideoxycytidine nucleotide analog against tumors up-regulating DNA polymerase beta. Mol Pharmacol60, 553–558.
ZhangZ, LiuX, SchroederJP, ChanCB, SongM, YuSP, WeinshenkerD, YeK (2014) 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology39, 638–650.
HenekaMT, KummerMP, StutzA, DelekateA, SchwartzS, Vieira-SaeckerA, GriepA, AxtD, RemusA, TzengTC, GelpiE, HalleA, KorteM, LatzE, GolenbockDT (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature493, 674–678.
19.
KasaiN, MizushinaY, MurataH, YamazakiT, OhkuboT, SakaguchiK, SugawaraF (2005) Sulfoquinovosylmonoacylglycerol inhibitory mode analysis of rat DNA polymerase beta. FEBS J272, 4349–4361.
20.
ScheffSW, PriceDA, SchmittFA, ScheffMA, MufsonEJ (2011) Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis24, 547–557.
21.
DongH, MartinMV, ChambersS, CsernanskyJG (2007) Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J Comp Neurol500, 311–321.
22.
El-KhodorBF, OoTF, KholodilovN, BurkeRE (2003) Ectopic expression of cell cycle markers in models of induced programmed cell death in dopamine neurons of the rat substantia nigra pars compacta. Exp Neurol179, 17–27.
23.
OsheroffWP, JungHK, BeardWA, WilsonSH, KunkelTA (1999) The fidelity of DNA polymerase beta during distributive and processive DNA synthesis. J Biol Chem274, 3642–3650.
24.
HerrupK, NeveR, AckermanSL, CopaniA (2004) Divide and die: Cell cycle events as triggers of nerve cell death. J Neurosci24, 9232–9239.
25.
CanitrotY, FrechetM, ServantL, CazauxC, HoffmannJS (1999) Overexpression of DNA polymerase beta: A genomic instability enhancer process. FASEB J13, 1107–1111.
26.
BorgN, StahleL (1998) Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2′,3′-dideoxycytidine) and BEA005 (2′, 3′-dideoxy-3′-hydroxymethylcytidine) in rats, studied by microdialysis. Antimicrob Agents Chemother42, 2174–2177.
27.
GibbsJE, ThomasSA (2002) The distribution of the anti-HIV drug, 2′3′-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J Neurochem80, 392–404.
28.
YarchoanR, PernoCF, ThomasRV, KleckerRW, AllainJP, WillsRJ, McAteeN, FischlMA, DubinskyR, McNeelyMC, et al. (1988) Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet1, 76–81.
29.
NiuJ, XiongJ, HuD, ZengF, NieS, MaoS, WangT, ZhangZ, ZhangZ (2017) 2′,3′-dideoxycytidine protects dopaminergic neurons in a mouse model of Parkinson’s disease. Neurochem Res42, 2996–3004.
30.
TerryRD, MasliahE, SalmonDP, ButtersN, DeTeresaR, HillR, HansenLA, KatzmanR (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol30, 572–580.
31.
SzeCI, TroncosoJC, KawasC, MoutonP, PriceDL, MartinLJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol56, 933–944.
